RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Financials
  4. Accounts payable

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$109.6B
P/E ratio
SummaryFinancials
Period EndAccounts payable (Million USD)YoY (%)
Dec 31, 2024413+13.18%
Dec 31, 2023365+20.07%
Dec 31, 2022304+55.85%
Dec 31, 2021195+25.69%
Dec 31, 2020155+77.08%
Dec 31, 201988-21.06%
Dec 31, 2018111+49.99%
Dec 31, 201774+20.41%
Dec 31, 201661-18.00%
Dec 31, 201575+5.26%
Dec 31, 201471+44.33%
Dec 31, 201349-51.30%
Dec 31, 2012101+35.70%
Dec 31, 201175+108.20%
Dec 31, 201036

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)